Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2–Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial - Concepedia

Concepedia

Publication | Open Access

Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2–Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial

DOI Full Paper Access

116

Citations

30

References

2023

Year

Tadaaki Nishikawa, Kosei Hasegawa, Koji Matsumoto, Masahiko Mori, Yasuyuki Hirashima, Kazuhiro Takehara, Kazuya Ariyoshi, Tomoyasu Kato, Shigehiro Yagishita, Akinobu Hamada,

Journal of Clinical Oncology

Abstract

Trastuzumab deruxtecan has efficacy in patients with UCS, regardless of HER2 status. The safety profile was generally consistent with that previously reported. Toxicities were manageable with appropriate monitoring and treatment.

References

	Year	Citations

Page 1